Stocks
JNJ Stock Drops Slightly Amid Positive Trial Results
Johnson & Johnson (JNJ) stock has seen a slight drop in value after opening at $268.54, down from its last closing price of $269.47. The company's innovative medicine segment focuses on various areas including immunology, infectious diseases, and oncology.
The MedTech segment includes interventional solutions, orthopaedics, surgery, and vision categories. JNJ has a market capitalization of $649.39B, placing it in the mega-capitalization category.
Recent news from Johnson & Johnson includes positive results from Phase 3 trials for its Caplyta medication, which is being studied as a treatment for bipolar I disorder. The company also reported that its PAPILLON study met its primary endpoint.